Added to YB: 2024-08-16
Pitch date: 2024-06-30
NVO [bullish]
Novo Nordisk A/S
-64.13%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 140.41
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
growth
Loomis Sayles International Growth Fund Portfolio Holding: Novo Nordisk A/S
NVO: Global leader in diabetes/obesity w/ 90% sales. 33% diabetes & 85% obesity market share. Q3 beat, FY guidance up 1%. GLP-1s (Wegovy/Ozempic) driving growth. 100M+ US obese patients. 40%+ new patient share. Double-digit rev/FCF growth expected. Shares undervalued despite Lilly competition. Ongoing innovation & execution key to long-term success.
Read full article (3 min)